Adagio Therapeutics Overview
- Founded
- 2020
- Status
- Public
- Employees
- 92
- Stock Symbol
- ADGI
- Share Price
- $5.02
- (As of Monday Closing)
Adagio Therapeutics General Information
Description
Adagio Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company's lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease 2019, or COVID-19, the disease caused by the virus SARS-CoV-2 and its variants.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- 1601 Trapelo Road
- Suite 178
- Waltham, MA 02451
- United States
+1 (781) 000-0000
Adagio Therapeutics Timeline
Adagio Therapeutics Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.02 | $5.03 | $4.88 - $78.82 | $560M | 111M | 8.57M |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Adagio Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Adagio Therapeutics‘s full profile, request access.
Request a free trialAdagio Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is available in the PitchBook Platform. To explore Adagio Therapeutics‘s full profile, request access.
Request a free trialAdagio Therapeutics Patents
Adagio Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11192940-B2 | Compounds specific to coronavirus s protein and uses thereof | Active | 10-Apr-2020 | 000000000 | 00 |
| US-20210324048-A1 | Compounds specific to coronavirus s protein and uses thereof | Pending | 10-Apr-2020 | 000000000 |
Adagio Therapeutics Executive Team (11)
Adagio Therapeutics Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Ajay Royan | Mithril Capital Management | Board Member | 000 0000 |
| Anand Shah | Adagio Therapeutics | Board Member | 000 0000 |
| Halley Gilbert JD | Self | Board Member | 000 0000 |
| Howard Mayer | Adagio Therapeutics | Board Member | 000 0000 |
| Marc Elia | M28 Capital | Board Member | 000 0000 |
Adagio Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAdagio Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore Adagio Therapeutics‘s full profile, request access.
Request a free trial